SBIO.US ALPS Medical Breakthroughs ETF
- Total assets
- 181M
- Expense ratio
- 0.50%
- Dividend yield
- -
- 1-year return
- +17.61%
- Holdings
- 100
- Since
- 2014
Fund data as reported by the issuer, updated Nov 17, 2026. Total assets are in the fund's base currency.
What does SBIO.US invest in?
- Mostly US stocks (89.8%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (90.8%)
- Top 3 holdings: 12.1% of the fund
Asset allocation
- US stocks 89.8%
- Non-US stocks 7.6%
Top holdings
- Oruka Therapeutics, Inc. 4.46%
- CG Oncology, Inc. Common stock 4.27%
- Veradermics, Incorporated 3.40%
- Dianthus Therapeutics Inc. 3.28%
- Edgewise Therapeutics Inc 3.21%
ALPS Medical Breakthroughs ETF performance
Sharpe ratio 1.01- This year
- +5.37%
- 1 year
- +17.61%
- 3 years
- +31.32%
- 5 years
- +4.12%
Volatility 25.5% over 1 year and 28.4% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
SBIO.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About ALPS Medical Breakthroughs ETF
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Full fund profileALPS Medical Breakthroughs ETF top holdings
32.4% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Oruka Therapeutics, Inc. ORKA.US | Healthcare | United States | 4.46% |
| CG Oncology, Inc. Common stock CGON.US | Healthcare | United States | 4.27% |
| Veradermics, Incorporated MANE.US | Healthcare | United States | 3.40% |
| Dianthus Therapeutics Inc. DNTH.US | Healthcare | United States | 3.28% |
| Edgewise Therapeutics Inc EWTX.US | Healthcare | United States | 3.21% |
| Travere Therapeutics Inc TVTX.US | Healthcare | United States | 3.02% |
| Definium Therapeutics, Inc. DFTX.US | Healthcare | United States | 2.96% |
| Relay Therapeutics Inc RLAY.US | Healthcare | United States | 2.72% |
| Xenon Pharmaceuticals Inc XENE.US | Healthcare | United States | 2.67% |
| Amylyx Pharmaceuticals Inc AMLX.US | Healthcare | United States | 2.42% |
The 10 largest of 100 holdings.
SBIO.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
SBIO.US regional exposure
- North America90.8%
- Europe Developed2.0%
- Asia Emerging1.9%
- United Kingdom1.5%
Share of the stocks in the fund.
Company size
Average market cap 2.38B- Medium cap1.8%
- Small cap25.2%
- Micro cap58.4%
ALPS Medical Breakthroughs ETF fund profile
- Fund name
- ALPS Medical Breakthroughs ETF
- Ticker
- SBIO.US
- Exchange
- USA Stocks
- Issuer
- ALPS
- Index tracked
- -
- Category
- Healthcare Equity
- Domicile
- United States
- Inception date
- Dec 30, 2014
- Trading currency
- USD
- Expense ratio
- 0.50%
- Annual turnover
- 0.8%
About ALPS Medical Breakthroughs ETF
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.